Macular edema in uveitic eyes. Chorioretinal inflammation, unspecified
Conditions
Interventions
the 1st group will receive 0.05 ml (1.25 mg) intravitreal Bevacizvmab (IVB).
Intervention 1: The eyes will randomly divided into two groups
the 1st group will receive 0.05 ml (1.25 mg) intravitreal Bevacizvmab (IVB). Intervention 2: The eyes will randomly divided into two groups
the 2nd group will recive 0.05ml (2mg) Triamcinolone acetonide intravitreally.
Treatment - Drugs
The eyes will randomly divided into two groups
Sponsors
Vice chancellor for research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
9 Years to 47 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with inactive uveitis, according to sun group classification, who had visual loss due to macular edema (diagnosed by optical coherence tomography (OCT)) and not responding to topical medication such as steroid. Exclusion criteria included any other ophthalmic disease that causes macular edema (e.g. diabetes, venous occlusive diseases); any intraocular surgery within 3 months of injection; media opacity that hinders assessment of macula by OCT, prior vitrectomy; Glaucoma; ocular hypertension and monocularity.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular thickness. Timepoint: 3, 6 and 12 months after injection of drug. Method of measurement: Optical Coherence Tomography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual acuity. Timepoint: 3, 6 and 12 months after injection. Method of measurement: Snellen chart. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mansour Rahimi
Shiraz University of Medical Sciences
Outcome results
None listed